From Reductionist Skills to Meaningful Learning: Trust and Humility in Bedside Cardiac Assessment

Συγγραφείς: Meisel JL, Navedo DD, Opole IO, Cohen GM, Bernard SA, Carmona H, Nahas AH, Eiduson CM, Papps N

Πηγή: Advances in Medical Education and Practice, Vol 16, Iss Issue 1, Pp 1305-1316 (2025)

Θεματικοί όροι: Competency-Based Medical Education, UME-GME Transition, Professional Identity Formation, Humility in Medical Education, Confident Humility, Trustworthiness in Health Professions Education, Special aspects of education, LC8-6691, Medicine (General), R5-920

Περιγραφή αρχείου: electronic resource

Relation: https://www.dovepress.com/from-reductionist-skills-to-meaningful-learning-trust-and-humility-in--peer-reviewed-fulltext-article-AMEP; https://doaj.org/toc/1179-7258

Σύνδεσμος πρόσβασης: https://doaj.org/article/80abeeae528c457ab20f69347af0d29d

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial

Συγγραφείς: Pfeiler, G, Author, Hlauschek, D, Author, Mayer, EL, Author, Deutschmann, C, Author, Kacerovsky-Strobl, S, Author, Martin, M, Author, Meisel, JL, Author, Zdenkowski, N, Author, Loibl, S, Author, Balic, M, Author, Pfeiler, G, Author, Hlauschek, D, Author, Mayer, EL, Author, Deutschmann, C, Author, Kacerovsky-Strobl, S, Author, Martin, M, Author, Meisel, JL, Author, Zdenkowski, N, Author, Loibl, S, Author, Balic, M, Author

Συνεισφορές: Pfeiler, G, Author, Hlauschek, D, Author, Mayer, EL, Author, Deutschmann, C, Author, Kacerovsky-Strobl, S, Author, Martin, M, Author, Meisel, JL, Author, Zdenkowski, N, Author, Loibl, S, Author, Balic, M, Author

Πηγή: JOURNAL OF CLINICAL ONCOLOGY. 41(33):5118-5130

Σύνδεσμος πρόσβασης: https://ki.se/en/research/search-research-information?t=2&query=id%3A632176

Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547] (The Breast (2025) 83, (S0960977625005648), (10.1016/j.breast.2025.104547))

Συγγραφείς: Demeestere, I, Niman, SM, Partridge, AH, Diego, DS, Kammler, R, Ruggeri, M, Colleoni, M, Shimizu, C, Saura, C, Gelmon, KA, Saetersdal, AB, Kroep, JR, Mailliez, A, Amant, F, Ruız-Borrego, M, Lee, JE, Kataoka, A, Walshe, JM, Takei, J, Borstnar, S, Borges, VF, Saunders, C, Susnjar, S, Bjelic-Radisic, V, Cardoso, F, Meisel, JL, Kawwass, JF, Spanic, T, El-Abed, S, Piccart, M, Korde, LA, Goldhirsch, A, Gelber, RD, Pagani, O, Azim, HA, Peccatori, FA

Relation: https://hdl.handle.net/11343/363596

Διαθεσιμότητα: https://hdl.handle.net/11343/363596

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer

Συγγραφείς: Weigelt, B, Comino-Méndez, I, de Bruijn, I, Tian, L, Meisel, JL, García-Murillas, I, Fribbens, C, Cutts, R, Martelotto, LG, Ng, CKY, Lim, RS, Selenica, P, Piscuoglio, S, Aghajanian, C, Norton, L, Murali, R, Hyman, DM, Borsu, L, Arcila, ME, Konner, J, Reis-Filho, JS, Greenberg, RA, Robson, ME, Turner, NC

Συνεισφορές: Cutts, Rosalind, Turner, Nicholas

Πηγή: Clinical Cancer Research. 23:6708-6720

Θεματικοί όροι: 0301 basic medicine, Adult, BRCA2 Protein, Ovarian Neoplasms, 0303 health sciences, BRCA1 Protein, Drug Resistance, Breast Neoplasms, Middle Aged, Poly(ADP-ribose) Polymerase Inhibitors, 3. Good health, 03 medical and health sciences, Drug Resistance, Neoplasm, Mutation, Neoplasm, Humans, Female, Cell-Free Nucleic Acids, Germ-Line Mutation, Aged, Platinum

Περιγραφή αρχείου: application/pdf; Print-Electronic

Σύνδεσμος πρόσβασης: https://clincancerres.aacrjournals.org/content/clincanres/23/21/6708.full.pdf
https://pubmed.ncbi.nlm.nih.gov/28765325

Abstract P6-17-26: Care 001: multi-center randomized open-label phase II trial of neoadjuvant trastuzumab emtansine (T-DM1) in combination with lapatinib and nab-paclitaxel compared with paclitaxel, trastuzumab and pertuzumab in HER2-neu over-expressed breast cancer patients (TEAL study)

Συγγραφείς: Creamer, SL, primary, Patel, TA, additional, Ensor, JE, additional, Rodriguez, AA, additional, Niravath, PA, additional, Darcourt, JG, additional, Kaklamani, VG, additional, Meisel, JL, additional, Li, X, additional, Zhao, J, additional, Kuhn, JG, additional, Rosato, RR, additional, Qian, W, additional, Belcheva, A, additional, Boone, T, additional, Chang, J, additional

Πηγή: Cancer Research. 2019/02/15

Abstract P3-10-25: Clinicopathologic factors associated with pCR to neoadjuvant anti-HER2-directed chemotherapy

Συγγραφείς: Meisel, JL, primary, Suo, A, additional, Taylor, CE, additional, Zhang, C, additional, Li, X, additional

Πηγή: Cancer Research. 2019/02/15

P2-19-02: Multidisciplinary Treatment of Pregnancy-Associated Breast Cancer.

Συγγραφείς: Meisel, JL, primary, Economy, KE, additional, Zabicki-Calvillo, K, additional, Gelber, S, additional, Kereakoglow, S, additional, Winer, EP, additional, Partridge, AH, additional, Mayer, EL, additional

Πηγή: Cancer Research. 2011/12/01

Quality of life in long-term survivors of metastatic breast cancer.

Συγγραφείς: Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH

Πηγή: Clinical Breast Cancer; 2012 Apr, Vol. 12 Issue 2, p119-126, 8p

Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.

Συγγραφείς: Meisel JL; Department of Hematology and Medical Oncology, Emory Winship Cancer Institute, Emory University, Atlanta, GA, USA., Chen C; AstraZeneca, Gaithersburg, MD, USA., Kris A; Flatiron Health, New York, NY, USA., Ru M; AstraZeneca, Gaithersburg, MD, USA., Pham T; AstraZeneca, Gaithersburg, MD, USA., Roose J; Flatiron Health, New York, NY, USA. james.roose@flatiron.com.

Πηγή: Breast cancer research and treatment [Breast Cancer Res Treat] 2026 Sep 09; Vol. 219 (2). Date of Electronic Publication: 2026 Sep 09.

Τύπος έκδοσης: Journal Article; Observational Study

Στοιχεία περιοδικού: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Estrogen Receptor alpha*/genetics , Breast Neoplasms*/genetics , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Mutation*, United States/epidemiology ; Biomarkers, Tumor/genetics ; Humans ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Treatment Outcome ; Adult ; Neoplasm Metastasis

Spatial Logic Reconciles Gene-signature Methods in Triple Negative Breast Cancer.

Συγγραφείς: Bastian W, Meisel JL, Lee JH, Shaker N, Griffiths L, Aiello M, Buchwald Z, Liu Y, Thompson EA, Li Z, Douglass EF, Li X

Πηγή: BioRxiv : the preprint server for biology [bioRxiv] 2026 Aug 14. Date of Electronic Publication: 2026 Aug 14.

Τύπος έκδοσης: Journal Article; Preprint

Στοιχεία περιοδικού: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE

Association between self-reported breast cancer knowledge and clinical trial participation in patients with triple-negative breast cancer.

Συγγραφείς: Tesch ME; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Graham N; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Snow C; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Stever CE; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Parker TS; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Luo M; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Martino IG; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Drummey B; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Virani S; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Santos K; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Bsat J; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Ryan S; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Beth Israel Deaconess Medical Center, Boston, MA, USA., Hughes ME; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Yale Cancer Center, New Haven, CT, USA., Wrabel E; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA., Tung N; Beth Israel Deaconess Medical Center, Boston, MA, USA., Lo S; Stamford Health, Stamford, CT, USA., Ahmad N; Berkshire Medical Center, Pittsfield, MA, USA., Faggen M; Dana-Farber Cancer Institute South Shore, Weymouth, MA, USA., Sinclair N; Dana-Farber Cancer Institute Milford and Foxborough, Milford, MA, USA., Constantinou M; Lifespan Comprehensive Cancer Center, Providence, RI, USA., Sinclair S; Northern Light Eastern Maine Medical Center, Bangor, ME, USA., Meisel JL; Winship Cancer Institute of Emory University, Atlanta, GA, USA., King TA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA.; Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Mittendorf EA; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA.; Division of Breast Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA., Tayob N; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Partridge AH; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Winer EP; Yale Cancer Center, New Haven, CT, USA., Tolaney SM; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA., Garrido-Castro AC; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Ana_Garrido-Castro@DFCI.HARVARD.EDU.; Harvard Medical School, Boston, MA, USA. Ana_Garrido-Castro@DFCI.HARVARD.EDU.

Πηγή: Breast cancer research and treatment [Breast Cancer Res Treat] 2026 Jul 30; Vol. 218 (2). Date of Electronic Publication: 2026 Jul 30.

Τύπος έκδοσης: Journal Article

Στοιχεία περιοδικού: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Triple Negative Breast Neoplasms*/therapy , Triple Negative Breast Neoplasms*/epidemiology , Triple Negative Breast Neoplasms*/psychology , Triple Negative Breast Neoplasms*/pathology , Health Knowledge, Attitudes, Practice* , Patient Participation* , Clinical Trials as Topic*, Humans ; Female ; Middle Aged ; Aged ; Self Report ; Neoplasm Staging ; Adult ; Prospective Studies

Antibody-drug conjugates in breast cancer.

Συγγραφείς: Sakach EA; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Meisel JL; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., McArthur HL; UT Southwestern Medical Center, Dallas, Texas, USA.

Πηγή: Cancer [Cancer] 2026 Jun 01; Vol. 132 Suppl 1, pp. e70420.

Τύπος έκδοσης: Journal Article; Review

Στοιχεία περιοδικού: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/immunology , Breast Neoplasms*/pathology , Immunoconjugates*/therapeutic use , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Female ; Animals

Negative 18 F-FES PET/CT Despite Estrogen Receptor Positivity by Immunohistochemistry.

Συγγραφείς: Lawal IO; Departments of Radiology and Imaging Sciences., Li X; Pathology and Laboratory Medicine, Emory University., Sakach EA; Departments of Hematology and Medical Oncology., Farley CR; Surgery., Meisel JL; Departments of Hematology and Medical Oncology., Baum Y; Departments of Radiology and Imaging Sciences., Chaudhary KK; Departments of Radiology and Imaging Sciences., Wang Q; Pathology and Laboratory Medicine, Emory University., Torres MA; Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Mankoff DA; Department of Radiology, University of Pennsylvania, Philadelphia, PA., Schuster DM; Departments of Radiology and Imaging Sciences.

Πηγή: Clinical nuclear medicine [Clin Nucl Med] 2026 Apr 01; Vol. 51 (4), pp. e244-e246. Date of Electronic Publication: 2025 Jun 06.

Τύπος έκδοσης: Journal Article; Case Reports

Στοιχεία περιοδικού: Publisher: Lippincott Country of Publication: United States NLM ID: 7611109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1536-0229 (Electronic) Linking ISSN: 03639762 NLM ISO Abbreviation: Clin Nucl Med Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Receptors, Estrogen*/metabolism , Breast Neoplasms*/diagnostic imaging , Breast Neoplasms*/metabolism , Breast Neoplasms*/pathology , Estradiol*/analogs & derivatives , Positron Emission Tomography Computed Tomography* , Positron-Emission Tomography*, Humans ; Female ; Immunohistochemistry ; Middle Aged

Improving CDK4/6 inhibitors adherence in breast cancer using the CONnected CUstomized Treatment Platform (CONCURxP) mobile health intervention: Study protocol for ECOG-ACRIN EAQ221CD.

Συγγραφείς: Sadigh G; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA, United States of America. Electronic address: gsadigh@uci.edu., Duan F; Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States of America., Gareen IF; Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States of America; Brown University School of Public Health Department of Epidemiology, Providence, RI, United States of America., Hancock J; Cancer Research for the Ozarks NCORP, Springfield, MO, United States of America., Sicks JD; Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States of America., Thangarajah M; Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States of America., Meisel JL; Winship Cancer Institute, Emory University, Atlanta, GA, United States of America., Torres MA; Winship Cancer Institute, Emory University, Atlanta, GA, United States of America., Ramsey SD; Hutchinson Institute for Cancer Outcomes Research, Seattle, WA, United States of America., Wolff AC; Sidney Kimmel Cancer Center, John Hopkins University, MD, United States of America., Wagner LI; University of North Carolina at Chapel Hill, NC, United States of America., Carlos RC; Columbia University, New York, NY, United States of America., Graetz I; Winship Cancer Institute, Emory University, Atlanta, GA, United States of America.

Πηγή: Contemporary clinical trials [Contemp Clin Trials] 2026 Jan; Vol. 160, pp. 108145. Date of Electronic Publication: 2025 Nov 18.

Τύπος έκδοσης: Journal Article; Clinical Trial Protocol

Στοιχεία περιοδικού: Publisher: Elsevier Country of Publication: United States NLM ID: 101242342 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-2030 (Electronic) Linking ISSN: 15517144 NLM ISO Abbreviation: Contemp Clin Trials Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/administration & dosage , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Medication Adherence*, Humans ; Female ; Text Messaging ; Telemedicine ; Randomized Controlled Trials as Topic ; Reminder Systems ; Quality of Life

Corrigendum to "Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial" [The Breast 83 (2025) 104547].

Συγγραφείς: Demeestere I; Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium; Gynecology and Obstetrics Department, Fertility Clinic, H.U.B Erasme Hospital, Brussels, Belgium. Electronic address: Isabelle.demeestere@ulb.be., Niman SM; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Diego DS; Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA., Kammler R; Translational Research Coordination, International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland., Ruggeri M; Program for Young Patients, International Breast Cancer Study Group, a division of ETOP IBCSG Partners Foundation, Bern, Switzerland., Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Shimizu C; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain., Gelmon KA; BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC, Canada., Saetersdal AB; Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Dutch Breast Cancer Research Group (BOOG), the Netherlands., Mailliez A; Department of Medical Oncology, Breast Cancer Unit, Centre Oscar Lambret, Lille, France., Amant F; Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium; Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, the Netherlands., Ruız-Borrego M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Virgen del Rocio Sevilla, Sevilla, Spain., Lee JE; Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea., Kataoka A; Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Walshe JM; Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland., Takei J; St Luke's International Hospital, Breast Center, Tokyo, Japan., Borstnar S; Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia., Borges VF; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA., Saunders C; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Royal Melbourne Hospital, Melbourne, VIC, Australia., Susnjar S; Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Bjelic-Radisic V; Breast Unit, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany; Austrian Breast and Colorectal Study Group (ABCSG), Austria., Cardoso F; Breast Unit, Champalimaud Foundation and Advanced Breast Cancer (ABC) Global Alliance, Lisbon, Portugal., Meisel JL; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Kawwass JF; Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA., Spanic T; Europa Donna, Ljubljana, Slovenia and Europa Donna - The European Breast Cancer Coalition, Milan, Italy., El-Abed S; Breast International Group, Brussels, Belgium., Piccart M; Breast International Group, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium., Korde LA; Breast and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Goldhirsch A; International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland; IEO, European Institute of Oncology, IRCCS, Milan, Italy., Gelber RD; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA; Frontier Science Foundation, Boston, MA, USA; Harvard TH Chan School of Public Health, Boston, MA, USA., Pagani O; Geneva University Hospitals, Geneva, Switzerland; Lugano University, Lugano, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Azim HA Jr; Cairo Cure Oncology Center, Cairo, Egypt., Peccatori FA; Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy.

Συλλογικό Έργο: International Breast Cancer Study Group and the POSITIVE Trial Collaborators

Πηγή: Breast (Edinburgh, Scotland) [Breast] 2025 Dec; Vol. 84, pp. 104570. Date of Electronic Publication: 2025 Sep 22.

Τύπος έκδοσης: Published Erratum

Στοιχεία περιοδικού: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE; In Process

Circulating Tumor Cell Dynamics after CDK4/6 Inhibitor for Hormone Receptor-Positive Metastatic Breast Cancer: A Biomarker Analysis from the PACE Phase II Study.

Συγγραφείς: Gerratana L; Department of Medicine, University of Udine, Udine, Italy.; Department of Medical Oncology, CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy., Reduzzi C; Department of Medical Oncology, Weill Cornell Medicine, New York, New York.; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Ren Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Jeselsohn R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Mahtani RL; Department of Medical Oncology, Miami Cancer Institute, Miami, Florida., Ma CX; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., DeMichele A; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Meisel JL; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia., Miller K; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana., Abdou Y; Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina., Riley EC; Department of Medicine, Brown Cancer Center, University of Louisville Health, Louisville, Kentucky., Qamar R; Aurora Cancer Care, Milwaukee, Wisconsin., Sharma P; Department of Medical Oncology, University of Kansas Medical Center, Westwood, Kansas., Reid SA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee., Ko N; Department of Medical Oncology, Boston Medical Center, Boston, Massachusetts., Liu Y; Pfizer, La Jolla, California., Gauthier E; Pfizer, La Jolla, California., Burstein HJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., DeMeo M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Regan MM; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Cristofanilli M; Department of Medical Oncology, Weill Cornell Medicine, New York, New York.; Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Mayer EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.

Πηγή: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Nov 03; Vol. 31 (21), pp. 4510-4517.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

Στοιχεία περιοδικού: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Neoplastic Cells, Circulating*/pathology , Neoplastic Cells, Circulating*/drug effects , Neoplastic Cells, Circulating*/metabolism , Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/blood , Breast Neoplasms*/mortality , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism , Cyclin-Dependent Kinase 4*/antagonists & inhibitors , Biomarkers, Tumor*/blood , Cyclin-Dependent Kinase 6*/antagonists & inhibitors , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Erb-b2 Receptor Tyrosine Kinases/metabolism ; Fulvestrant/administration & dosage ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/therapeutic use ; Pyridines/administration & dosage ; Humans ; Female ; Middle Aged ; Prognosis ; Aged ; Adult ; Neoplasm Metastasis ; Piperazines

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial.

Συγγραφείς: Demeestere I; Research Laboratory on Human Reproduction, Université Libre de Bruxelles (ULB), Brussels, Belgium; Gynecology and Obstetrics Department, Fertility Clinic, H.U.B Erasme Hospital, Brussels, Belgium. Electronic address: Isabelle.demeestere@ulb.be., Niman SM; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Diego DS; Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA., Kammler R; Translational Research Coordination, International Breast Cancer Study Group, a Division of ETOP IBCSG Partners Foundation, Bern, Switzerland., Ruggeri M; Program for Young Patients, International Breast Cancer Study Group, a Division of ETOP IBCSG Partners Foundation, Bern, Switzerland., Colleoni M; Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Italy., Shimizu C; Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan., Saura C; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain., Gelmon KA; BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC, Canada., Saetersdal AB; Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; Dutch Breast Cancer Research Group (BOOG), the Netherlands., Mailliez A; Department of Medical Oncology, Breast Cancer Unit, Centre Oscar Lambret, Lille, France., Amant F; Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium; Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, the Netherlands., Ruız-Borrego M; GEICAM Spanish Breast Cancer Group, Madrid, Spain; Hospital Virgen Del Rocio Sevilla, Sevilla, Spain., Lee JE; Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea; Department of Clinical Research and Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea., Kataoka A; Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Walshe JM; Cancer Trials Ireland, Dublin, Ireland; Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland., Takei J; St Luke's International Hospital, Breast Center, Tokyo, Japan., Borstnar S; Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia., Borges VF; Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO, USA., Saunders C; Department of Surgery, University of Melbourne, Melbourne, VIC, Australia; Royal Melbourne Hospital, Melbourne, VIC, Australia., Susnjar S; Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Bjelic-Radisic V; Breast Unit, Helios University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany; Austrian Breast and Colorectal Study Group (ABCSG), Austria., Cardoso F; Breast Unit, Champalimaud Foundation and Advanced Breast Cancer (ABC) Global Alliance, Lisbon, Portugal., Meisel JL; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA., Kawwass JF; Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA, USA., Spanic T; Europa Donna, Ljubljana, Slovenia and Europa Donna - The European Breast Cancer Coalition, Milan, Italy., El-Abed S; Breast International Group, Brussels, Belgium., Piccart M; Breast International Group, Brussels, Belgium; Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium., Korde LA; Breast and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA., Goldhirsch A; International Breast Cancer Study Group, Division of ETOP IBCSG Partners Foundation, Bern, Switzerland; IEO, European Institute of Oncology, IRCCS, Milan, Italy., Gelber RD; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, MA, USA; Frontier Science Foundation, Boston, MA, USA; Harvard TH Chan School of Public Health, Boston, MA, USA., Pagani O; Geneva University Hospitals, Geneva, Switzerland; Lugano University, Lugano, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Azim HA Jr; Cairo Cure Oncology Center, Cairo, Egypt., Peccatori FA; Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy.

Συλλογικό Έργο: International Breast Cancer Study Group and the POSITIVE Trial Collaborators

Πηγή: Breast (Edinburgh, Scotland) [Breast] 2025 Oct; Vol. 83, pp. 104547. Date of Electronic Publication: 2025 Jul 26.

Τύπος έκδοσης: Journal Article; Multicenter Study

Στοιχεία περιοδικού: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/blood , Ovarian Reserve*/physiology , Primary Ovarian Insufficiency*/blood , Antineoplastic Agents, Hormonal*, Anti-Mullerian Hormone/blood ; Fertility Preservation/methods ; Follicle Stimulating Hormone/blood ; Progesterone/blood ; Prolactin/blood ; Thyrotropin/blood ; Adult ; Female ; Humans ; Pregnancy ; Chemotherapy, Adjuvant ; Fertility ; Premenopause

Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2- advanced or metastatic breast cancer: phase 1/2 study results.

Συγγραφείς: Hamilton EP; Sarah Cannon Research Institute, 335 24th Ave North Ste 300, Nashville, TN, 37203, USA. erika.hamilton@scri.com., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Borges VF; Anschutz Medical Campus, University of Colorado Cancer Center, Aurora, CO, USA., Meisel JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Okera M; Cancer Research SA, Adelaide, SA, Australia., Alemany CA; AdventHealth Cancer Institute, Orlando, FL, USA., Pluard TJ; Saint Luke's Cancer Institute - Koontz Center for Advanced Breast Cancer, Kansas City, MO, USA., Wesolowski R; Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Sabanathan D; Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, USA., Conlin AK; Providence Cancer Institute, Portland, OR, USA., McCarthy N; ICON Cancer Centre, Auchenflower, QLD, Australia., Shaw M; Olema Oncology, San Francisco, CA, USA., Tonda M; Olema Oncology, San Francisco, CA, USA., Shilkrut M; Olema Oncology, San Francisco, CA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Πηγή: Breast cancer research : BCR [Breast Cancer Res] 2025 Jul 01; Vol. 27 (1), pp. 119. Date of Electronic Publication: 2025 Jul 01.

Τύπος έκδοσης: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't

Στοιχεία περιοδικού: Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100927353 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-542X (Electronic) Linking ISSN: 14655411 NLM ISO Abbreviation: Breast Cancer Res Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism , Estrogen Receptor Antagonists*/administration & dosage , Estrogen Receptor Antagonists*/therapeutic use , Estrogen Receptor Antagonists*/pharmacokinetics , Estrogen Receptor Antagonists*/adverse effects , Pyridines*/administration & dosage , Pyridines*/pharmacokinetics , Pyridines*/therapeutic use , Pyridines*/adverse effects, Erb-b2 Receptor Tyrosine Kinases/metabolism ; Erb-b2 Receptor Tyrosine Kinases/genetics ; Receptors, Estrogen/metabolism ; Receptors, Estrogen/antagonists & inhibitors ; Estrogen Receptor alpha/genetics ; Estrogen Receptor alpha/antagonists & inhibitors ; Humans ; Female ; Middle Aged ; Aged ; Adult ; Administration, Oral ; Mutation ; Neoplasm Metastasis

Erratum: Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.

Συγγραφείς: Meisel JL, Venur VA, Gnant M, Carey L

Πηγή: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting [Am Soc Clin Oncol Educ Book] 2025 Jun; Vol. 45 (3), pp. e201037CX1. Date of Electronic Publication: 2025 Sep 25.

Τύπος έκδοσης: Journal Article; Published Erratum

Στοιχεία περιοδικού: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101233985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1548-8756 (Electronic) Linking ISSN: 15488748 NLM ISO Abbreviation: Am Soc Clin Oncol Educ Book Subsets: MEDLINE; In Process

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

Συγγραφείς: Naughton MJ; The Ohio State University, Columbus, USA. Electronic address: Michelle.Naughton@osumc.edu., Zahrieh DM; Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, USA., Gnant M; Medical University of Vienna AT, Vienna, Austria; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., Zdenkowski N; University of Newcastle, Callagan, Australia., Lemieux J; Center Hospitalier Universitaire de Quebec, Universite Laval, Quebec City, Canada., Mao JJ; Memorial Sloan Kettering Cancer Center, New York City, USA., Bjelic-Radisic V; University Witten/Herdecke, Wuppertal, Germany., Shinn E; MD Anderson Cancer Center, Houston, USA., Balic M; Medical University Graz, Graz, Austria., Thomssen C; Universitatsfrauenklinik-Halle, Wittenberg, Germany., Meisel JL; Emory University, Atlanta, USA., Ruiz GM; European Medical Center, Moscow, Russia., Loibl S; German Breast Group, Neu-Isenburg, Germany., Isaacs C; Georgetown University, Washington, USA., Cameron D; Cancer Research UK Edinburgh Center, Edinburgh, UK., Henao-Carrasco FM; Hospital Virgen Macarena Sevilla, Seville, Spain and the GEICAM Collaborative Group., Goetz MP; Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, USA; Mayo Clinic, Rochester, MN, USA., Singer CF; Breast Centre, Sankt Veit an der Glan, Austria., Werutsky G; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Rugo HS; University of California, San Francisco, USA., Vetter M; University Hospital Basel, Basel, Switzerland., Tseng LM; Taipei Veterans General Hospital, Taipei, Taiwan., Miller K; Indiana University Simon Cancer Center, Indianapolis, USA., Fitzal F; Medical University of Vienna AT, Vienna, Austria; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., Gil Gil JM; Catalan Institute of Oncology, Barcelona, Spain., Park H; Washington University School of Medicine, St. Louis, USA., Linderholm B; Karolinska Institute, Solna, Sweden., Bajetta E; Institute of Oncology, Polyclinic Hospital, Monza, Italy., Dayao Z; University of New Mexico Hospital, Albuquerque, USA., Prat A; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria; Hospital Clinic Barcelona, Barcelona, Spain., Ehrhardt K; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., Metzger O; Dana-Farber Cancer Institute, Boston, USA., Arahmani A; Breast International Group, Brussels, Belgium., Law EH; Pfizer, Inc., New York City, USA., Partridge AH; Dana-Farber Cancer Institute, Boston, USA., Carey LA; University of North Carolina, Chapel Hill, USA., Zoroufy A; Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Rochester, USA., Dueck AC; Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Phoenix, USA., O'Brien P; Alliance Foundation Trials Statistics and Data Center, Mayo Clinic, Phoenix, USA., Hlauschek D; Austrian Breast and Colorectal Cancer Study Group (ABCSG), Vienna, Austria., DeMichele A; University of Pennsylvania, Philadelphia, USA., Mayer EL; Dana-Farber Cancer Institute, Boston, USA.

Πηγή: ESMO open [ESMO Open] 2025 Jun; Vol. 10 (6), pp. 105120. Date of Electronic Publication: 2025 Jun 04.

Τύπος έκδοσης: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III

Στοιχεία περιοδικού: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

Ιατρικοί όροι (MeSH): Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Piperazines*/therapeutic use , Piperazines*/administration & dosage , Pyridines*/therapeutic use , Pyridines*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Agents, Hormonal*/therapeutic use , Quality of Life*, Chemotherapy, Adjuvant/methods ; Humans ; Female ; Middle Aged ; Aged ; Adult ; Patient Reported Outcome Measures